The data demonstrate that CAR-M exhibited significantly enhanced phagocytic efficacy against CD26-positive cells compared to CD26-negative cells, suggesting that CD26 CAR-M cell therapy may represent a promising treatment modality for CML. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.